Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth
- 19 June 2015
- journal article
- Published by Springer Nature in Tumor Biology
- Vol. 36 (11) , 9067-9072
Abstract
The discoveries of recent decade showed that all critical changes in cancer cells, such as silencing of tumor-suppressor genes and activation of oncogenes, are caused not only by genetic but also by epigenetic mechanisms. Although epigenetic changes are somatically heritable, in contrast to genetic changes, they are potentially reversible, making them good targets for therapeutic intervention. Covalent modifications of chromatin such as methylation and acetylation of histones and methylation of DNA are the important components of epigenetic machinery. In this study, we investigated the effect of different modulators of DNA and histone covalent-modifying enzymes on the proliferation and viability of normal adult stem cells, such as human bone marrow mesenchymal stem cells (hMSCs), and on malignant tumor cells, such as glioblastoma (GB) D54 cells. Results demonstrated that specific combinations of histone methyltransferases and deacetylases inhibitors significantly attenuated D54 cells viability but having only a small effect on hMSCs growth. Taken together, these studies suggest that specific combinations of histone covalent modifiers could be an effective treatment option for the most aggressive type of primary brain tumors such as glioblastoma multiforme.Keywords
This publication has 34 references indexed in Scilit:
- Epigenetic modulators promote mesenchymal stem cell phenotype switchesThe International Journal of Biochemistry & Cell Biology, 2015
- EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cellsCancer Cell International, 2015
- Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cellsMolecular and Cellular Biochemistry, 2014
- Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck CancerPLOS ONE, 2013
- Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic EventsJournal of Signal Transduction, 2012
- EZH2 Is Essential for Glioblastoma Cancer Stem Cell MaintenanceCancer Research, 2009
- Expression profile of class I histone deacetylases in human cancer tissuesOncology Reports, 2007
- The Epigenomics of CancerCell, 2007
- DNA Methyltransferase Inhibitors for Cancer TherapyThe Cancer Journal, 2007
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006